Merck acquires Chinese supplier

February 11, 2011

Merck KGaA has acquired Beijing Skywing Technology, a supplier of cell-culture media products related technical services and bioreactors for the Chinese biopharmaceutical industry, for ¥120 million.

Merck KGaA has acquired Beijing Skywing Technology, a supplier of cell-culture media products related technical services and bioreactors for the Chinese biopharmaceutical industry, for ¥120 million.

“The acquisition allows Merck to immediately establish a direct presence in this market segment in China with access to an attractive and innovative cell-culture media portfolio, close relationships to local customers, a skilled management team and a high-quality facility”, said Burghard Freiberg, head of the business field pharm chemicals solutions of the Merck Millipore division. He says that these capabilities will enable the company to “strengthen the upstream processing offer to customers in China so that they can manufacture biopharmaceuticals safely and efficiently.”

Discussing the acquisition, Dr Matthias Bucerius, head of sales Asia, pharm chemicals solutions of the Merck Millipore division, said “Beijing Skywing Technology is one of the leading players in the cell-culture media market in China with very close business relationships to vaccine manufacturers and an excellent reputation in the local biotech industry. In addition, this access to the Chinese biopharmaceutical market can be utilized to leverage other Merck Millipore consumables sales like chromatography media, filtration devices and disposable bioreactor solutions.”

For more information on the company, visit www.merck.de